8/11/2019 150914_CLS-Corp

1/53

!"#$"%&"' )*+,

Engineered T cell therapies

A new paradigm in oncology

8/11/2019 150914_CLS-Corp

2/53

This communication expressly or implicitly contains certain forward-lookingstatements concerning Cellectis SA and its business.

Such statements involve certain known and unknown risks, uncertainties andother factors, which could cause the actual results, financial condition,

performance or achievements of Cellectis SA to be materially different from anyfuture results, performance or achievements expressed or implied by suchforward-looking statements.

Cellectis SA is providing this communication as of this date and does notundertake to update any forward-looking statements contained herein as a

result of new information, future events or otherwise.

Cellectis proprietary information.

Not to be copied, distributed or used without Cellectiss prior written consent.

FORWARD LOOKING STATEMENT

!"#$"%&"' )*+, 2

8/11/2019 150914_CLS-Corp

3/53

Brief introduction to Cellectis

8/11/2019 150914_CLS-Corp

4/53

!"#$"%&"' )*+,

Cellectis in brief

Discovery and development in engineered T cell therapy for oncology Paris France

NYSE Alternext Paris (ALCLS)

27.9 M shares outstanding (32.5 fully diluted) - !319 M market cap1

73 employees

Corporate

Technologies

Products 12 programs one preclinical proof of concept

Lead product: UCART19 allogeneic T cell for ALL and CLL

Phase I planed for Q3 - 2015

Partnerships Series of agreements since inception with recurrent revenues

An alliance with Servier on UCART19 and 5 targets in solid tumorsAn alliance with Pfizer on 15 targets in oncology

Engineered T cell CAR 5thgeneration immunotherapy

Nuclease based genome engineering TALEN, meganucleases

Proprietary electroporation technologies PulseAgile

>120 patents granted and over 355 patent applications

4

Subsidiary 1 fully owned subsidiary: Cellectis plant sciences in New Brighton, MN (14 FTE)

1August 29, 15 2014

8/11/2019 150914_CLS-Corp

5/53

Core technology

8/11/2019 150914_CLS-Corp

6/53

8/11/2019 150914_CLS-Corp

7/53

!"#$"%&"' )*+,

GENE SPECIFIC

AT A SAFE HARBOR LOCUSFOR GENECOMPLEMENTATION

AT THE GENE LOCUS

TALEN cut DNA at a unique target site(30 base pairs recognition site)

Induce an opening in DNA to allowsequence insertion, deletion and/or repair

Pioneer and leader in genome engineering: core technology

7

8/11/2019 150914_CLS-Corp

8/53

A new paradigm in the treatment of cancer

8/11/2019 150914_CLS-Corp

9/53

!"#$"%&"' )*+,

CAR T cells the 4thgeneration of mAb technology

Anti-CD3

Anti-tumor

Ag

TCR/CD3

Naked Ab Ab-DrugConjugate

Bi-specific CAR T cell

9

8/11/2019 150914_CLS-Corp

10/53

8/11/2019 150914_CLS-Corp

11/53

!"#$"%&"' )*+, 11

Immunotherapy breakthrough with CAR T cells

Diseases Patientstreated

CR2

N (%)PR3

N (%)Patientsresponding4

N (%)

CLL 32 7 (22%) 8 (25%) 15 (47%)

ALL 22 19 (86%) NC NC

Results from pilot trials testing CTL019 for CD19+ malignancies(UPenn/Novartis)1 presented at ASH 2013

1 Results communicated at ASH, December 20132 CR: complete remission3 PR: partial remission4 CR+PR

CARs in the clinics: the numbers!

33 ongoing clinical trials with CARs (all autologous)! Over 300 patients recruited! Impressive results on liquid tumors are changing the paradigm of cancer

treatment

8/11/2019 150914_CLS-Corp

12/53

!"#$"%&"' )*+,

Cellectis platform the 5thgeneration of mAb technology

Anti-CD3

Anti-Tumor Ag

TCR/CD3

Naked Ab Ab-DrugConjugate Bi-specific CAR T cell

12

Cellectis

EngineeredCAR T cell

First focus on:

"Allogeneic cells: by removing capacity for alloreactivity

" Enhance cell engraftment (resistance to chemotherapy)

" Enhance T cell potency (checkpoint inactivation)

8/11/2019 150914_CLS-Corp

13/53

!"#$"%&"' )*+,

Cellectis revolutionizing T cell CAR adoptive immunotherapy

13

1. Best in class gene editing technology: TALEN

2. Proprietary CAR platform technology

3. A cGMP manufacturing process

4. Broad preclinical and clinical portfolio with proprietary innovative features

5. Reduced time to market

6. Contained costs of goods

The 6 key features of Cellectis T cell adoptive immunotherapy platform

8/11/2019 150914_CLS-Corp

14/53

!"#$"%&"' )*+, 14

Cellectis engineered T cells for improved clinical outcomes

1 Allogeneic, non alloreactive Off the shelf product

2 Resistant to chemotherapy Compatible with SoCUse in combination therapies

3 Resistant to lymphodepleting agents Enhanced engraftment

4 Resistant to tumor inhibition Enhanced efficacy

5 Suppressed cross T cell reaction Better suited for specific tumors

6 Bispecific Ab enabled T cells For a combinatorial use

Enhancing the potential of T cells through genome engineering

The future of T cell therapies is in genome engineering

8/11/2019 150914_CLS-Corp

15/53

!"#$"%&"' )*+,

Cellectisbest in class technology

Current CAR T cell therapies : autologous Good efficacy with no GvHD and no rejection

Significant patient to patient variability

High cost of goods and complex logistics

Major limitations in market access

Allogeneic treatment: off-the-shelf frozen pharmaceutical product

Fixed dose and superior efficacy

Cost effective GMP manufacturing process (70-80% gross profit range)

Broad market access Risk mitigation through suicide receptor

Strong IP position on process and TALEN

Cellectis allogeneic CAR T cell platform

15

8/11/2019 150914_CLS-Corp

16/53

!"#$"%&"' )*+,

scFvs targeting different epitopesscFvs with variable affinities

Multiple hinge/transmembrane structures

Co-stimulatory domain (CD28 vs 41BB)

Key considerations for the optimal CAR

Tuning up CAR development

12

8/11/2019 150914_CLS-Corp

17/53

!"#$"%&"' )*+,

CD123 CAR: reaching the targetImpact of the hinge domain length on CAR activity

long hinge medium hinge short hingeNegative Control

!" !$ "%&'

(

)* +,-./0 +12

long hinge

medium hinge

short hinge

14

8/11/2019 150914_CLS-Corp

18/53

!"#$"%&"' )*+,

Plasmamembrane

1stgenerationCAR

2ndgenerationCAR

3rdgenerationCAR

Cellectis proprietarymultichain CAR

18

The next generation CARs: multichains multiply potentials

8/11/2019 150914_CLS-Corp

19/53

!"#$"%&"' )*+,

*-

+*-

)*-

.*-

,*-

/*-

0*-

123 456 %7 456 , 8 9':$ :7 456 ;;

34564789:4,;64

8/11/2019 150914_CLS-Corp

20/53

!"#$"%&"' )*+,

*

8/11/2019 150914_CLS-Corp

21/53

!"#$"%&"' )*+,

Glucocorticoid resistant T cells by genome editing

100

200

GR TALENCTL

ND D ND D

50

76%indels

500

2 Gy irradiated

NSG mice

Human

T cells

GR TALENelectroporation

T cell injection

Analysis of GR genecleavage effciency

10 days 2 weeks

dailydexamethasone

treatment

Mice sacrificed

GR

GAPDH

TALEN- + +

Dex - - +

Purification ofhuman T cells fromspleen

Analysis of GRexpression byWestern blot:

In vivo, GR TALEN-treated T cells resist to glucocorticoid treatment

Only GR-negative cells survive in vivodexamethasone treatment

Engraftmentanalysis

5 days

21

8/11/2019 150914_CLS-Corp

22/53

!"#$"%&"' )*+, 22

Resistance to standard of care: fludarabine resistant T cells

Inactivation of deoxycytidine kinase enables CD19 CAR T cells to resist to Fludarabine andClofarabine

Cmax

oral i.v.

Cmax

)@$(& A+B C

- + -

D A9=. ED A9=.

+74 GE H*I

J8

A9=. 3,.8 (K

mutatedalleles

wt alleles

8/11/2019 150914_CLS-Corp

23/53

!"#$"%&"' )*+,

Overcoming checkpoint inhibition:

PD-1 inactivation overcome suppressive impact of PDL-1

23

Cytotoxicity assay

Targetcelllys

is(%)

Targetcelllysis(%)

CAR/PD1-KO T Cell have improved cytotoxic capacityagainst PDL-1 expressing cells

PD-1 KO in T cells in a local solution to a local problem

8/11/2019 150914_CLS-Corp

24/53

!"#$"%&"' )*+,

A solid IP foundation

24

Patents on the process! TALEN! Electroporation (Cytopulse)! Methods on engineering of allogeneic T cells

Patent applications protecting first product (UCART19)

Patent applications protecting the platform and further products! Specific CARs! Multisubunit CARs! Bispecific/multispec CARs! Engineering methods for allogeneic T cells!

Modular allogeneic T cells to be used with bispecific antibodies

Cellectis proprietary or in licensed IP on Process/Products

8/11/2019 150914_CLS-Corp

25/53

GMP-compatible manufacturing process

8/11/2019 150914_CLS-Corp

26/53

!"#$"%&"' )*+,

Our platform: towards a universal adoptive T cell immunotherapy

Off-the-shelf (TCR disruption1)

Avoiding GvHD

CAR expression to redirect T cells totumor antigens

Suicide gene for safety

Other gene editing

Engineered

1 Knock-out by using TALEN2 Allogeneic CAR T cell targeting CD19+ malignancies

" For UCART192- CD52 disruption1toprevent destruction by high risk CLL mAb

Alemtuzumab therapy" Other gene disruptions/mutations in further

programs

SG SG

Enhance killer T cells by genome engineering

26

8/11/2019 150914_CLS-Corp

27/53

!"#$"%&"' )*+,

HealthyDonor

ApheresisFrozen PBMC

Patients

109 T cells 109 T cells

Efficiency >70%

2 x 109T cells100X

2x 1011 T cells

Double KO Efficiency >50%

1 x 1010 CAR+TCR-T cells>40% CD52KO

Off the shelfcell therapy product

27

Qualifyingtesting

ActivationT cells

D0

Transduction

D3

ElectroporationTALEN mRNA

D5

Cell Separation

D17

An established cost effective manufacturing process platform

!A robust process designed for cGMP compatibility

!

A short manufacturing cycle (< 20 days)

8/11/2019 150914_CLS-Corp

28/53

!"#$"%&"' )*+,

UCART19 - Consistency of manufactured product

28

Cell surface phenotype

Expansion /transduction intra and inter process robustness

Cell expansionTransduction efficiency

CD45RA

CD62L

8/11/2019 150914_CLS-Corp

29/53

!"#$"%&"' )*+,

Cellectis proprietary technology for TALENTMelectroporation

29

Proprietary large volumeelectroporation chamber

Electroporation system Proprietary cGMPElectroporation buffer

Proprietary PulseAgile electroporation waveform

A series of high voltage, short duration pulses followed

by lower voltage, longer duration pulses

" High transfection efficacy

" High cell viability

V

time

8/11/2019 150914_CLS-Corp

30/53

!"#$"%&"' )*+,

Simultaneous inactivation: TCR#and CD52

CD52

TCR/CD3

Simultaneous inactivation rates of TCR and CD52 over 50% of triple KO

+1LC 97A)+M

TALEN mRNA electroporation" development and optimization of TALEN targeting TCR#and CD52" optimization of proprietary electroporation process for T cell transfection

30

8/11/2019 150914_CLS-Corp

31/53

!"#$"%&"' )*+,

C. June trial (UPenn)41BB-!CAR in CLL, ALL

" CR with 1.1x109CAR T cells

" PR* with 5.8x108CAR T cells

" CR with 1.4x107CAR T cells

M. Sadelain trial (Memorial Sloan Kettering)

CD28-!CAR in adult ALL

" Patients received approximately 1-3x108cells

High productivity foreseen for Cellectis' process

One donor109cells

1010UCART19 cells

Treatment of1000 patients with

107cells per treatment

31

Cellectis process

! Contained manufacturing COGs (

8/11/2019 150914_CLS-Corp

32/53

!"#$"%&"' )*+,

Fast track from target choice to lead selection: 6 - 7 months

32

CHOICE OF TUMOR ASSOCIATED ANTIGEN(S)(TAA)

CAR DESIGN

Design and constructionof candidate CARs

CAR T CELL ENGINEERINGFirst tests on CAR T cell

GO/NO GO

In VitroAssay

development/ Target cell

engineering

5-6 months

1 month

TIMELINESUCART PROGRAM

CHOICE OF

ATTRIBUTES ANDNUCLEASE DESIGN 1

IN VITRO ASSAYS

Functional in vitro tests on target cellSelection of lead CAR

IDENTIFICATION OF TAA-SPECIFIC MAB(S) OROTHER LIGANDS

8/11/2019 150914_CLS-Corp

33/53

Lead product UCART19

8/11/2019 150914_CLS-Corp

34/53

!"#$"%&"' )*+,

# UCART19 first product for CLL and ALL

" Preclinical development ongoing with in vivo POC established

" Manufacturing process established, fully cGMP compatible Q4 2014

"Alliance with UCL in place for first in man studies

# Phase I Q3 2015

" Clinical Development plan in place

UCART19 development status: where we stand

34

8/11/2019 150914_CLS-Corp

35/53

!"#$"%&"' )*+,

Cellectis UCART19 cells induce CD19+ cell destruction in vitro

NT CAR

CD19

CD19

CD19

CD19

CD3 CD3

CD3CD3

SupT1-CD19 cells

SupT1-CD19 cells

SupT1 cells SupT1 cells

T cells transduced with vectorencoding Cellectis CD19 CAR

35

Efficient CAR-induced destructionof CD19+ target cells

8/11/2019 150914_CLS-Corp

36/53

!"#$"%&"' )*+,

UCART19 CAR: superior in vitro cytolytic capability

36

Target cell lysis by Cr51release

Benchmarked againstFMC63-41bb-zeta CAR (used by UPENN)

@+*

*

+*

)*

.*

,*

/*

0*J*

=*

.*K+ +/K+ =K+ .K+

>?

:F#"

CB+.0))

:F#"

CB+.0),%celllysis Benchmark CAR

Ctx CAR final version

Effector:Target

@/

*

/

+*

+/

)*

)/

.*

.*K+ +/K+ =K+ .K+

>?

:F#"

CB+.0))

:F#"

CB+.0),

%celllysis

Effector:Target

Benchmark CAR

Ctx CAR final version

@+*

*

+*

)*

.*

,*

/*

0*

J*

=*

.*K+ +/K+ =K+ .K+

>?

:F#"

CB+.0))

:F#"

CB+.0),

%celllysis

Effector:Target

Benchmark CAR

Ctx CAR final version

RAJI (CD19 positive Burkitts lymphoma cells)SUPT1-CD19

SUPT1CD19 negative cells

CD19 expressing cells

UCART19 CAR exhibits comparable/higher cytolytic capability than benchmarkCAR on target cells

8/11/2019 150914_CLS-Corp

37/53

!"#$"%&"' )*+,

PMA/Iono

TCR!+

CD52+

K562(CD19-)

Stim.:

CD107A

+ + -

-Daudi

(CD19+)

- +"CD19-CAR:

NT CAR

TCR#+CD52+

NT CAR

TCR#KO

CD52KO

TCR"& CD52 double KO does not impact in vitro activity of the CAR

In vitro antitumor reactivity is comparable in wt or CD52/TCR KO cells

TCR!KO

CD52KO

FSC

Daudi(CD19+)

37

8/11/2019 150914_CLS-Corp

38/53

!"#$"%&"' )*+,

wt cellsTCR- cells

Activation marker: CD25

wt cells TCR- cells

nostimulation

+ TCRstimulation

No functional T cell receptor for GvHD

Activation marker: CD69

TCR-deficient cells cannot

be activated via TCR

38

8/11/2019 150914_CLS-Corp

39/53

!"#$"%&"' )*+,

Anti-tumor potency UCART19 / benchmark CAR

1.44 Gy

Daudi

Non modified

1.44 GyDaudi

UCART19

Day 0

Day 1

Day 2

Day 3

Day 4

1.44 Gy

Daudi

Benchm. CAR

Day 4Before

T cells

treatment

Day 7

Day 21

1.44 Gy

Daudi

UCART19

1.44 Gy

Daudi

CAR

1.44 Gy

Daudi

Benchm. CAR

5/5tumor progression

5/5 3/3 5/5 5/5 5/5

Tumor model: 1x106Daudi-Luc cells injected in NOG micemice treated with 4x106CAR T cells

Tumor cells elimination

39

8/11/2019 150914_CLS-Corp

40/53

!"#$"%&"' )*+,

UCART19 cells eradicate lymphoma in vivo inpresence of lymphodepleting mAb

In collaboration with Dr. Martin Pule, University College London

40

Raji

18 h

3days

13days

alemtuzumabRaji

UCART19

alemtuzumabRaji

Day -1

Day 0

Day +1

6/6tumor

progression

6/6tumor

progression

6/6 CR5/7 CR2/7 PR

RajiUCART19

8/11/2019 150914_CLS-Corp

41/53

!"#$"%&"' )*+,

TCR-deficient T cells do not induce GvHD in vivo

Mean body weight

G2, fresh non modified T cells

G4, mock transfected T cells

G3, non modified T cells, cultured 15 days

G5, TCR# -/- T cells

G1, No T cells

! GvHD development, associated with body weight loss, in all mice injected with non modified T cells

! With TCR-deficient T cells: no clinical symptoms of GvHD observed

NOG mice irradiated (2.5 Gy) 1 day before T cell injection (i.v., 30x106 cells)

41

8/11/2019 150914_CLS-Corp

42/53

!"#$"%&"' )*+,

Exploratory Phase I/IIadult refractory ALL

Phase I/IIaRescue therapyin adult relapsed

ALL

Phase IIbRescue therapyin adult relapsed

ALL

Paediatric Investigational Plan

ALL : 2nd& 1stcomplete

remissionconsolidation

therapy

42

UCART19 clinical development overview

Market. Auth

ExploratoryPhase I/IIrescue therapy high

risk CLL

Phase I/IIaconsolidation

therapy inrelapsed CLL

CLL Rescue therapy inRefractory relapsed

CLL in second lineMRD+ consolidation

Therapy

UCART19 Clinical Development: CLL

UCART19 Clinical Development: ALL

Phase IIB(confirmatory)consolidation

therapy inrelapsed CLL

Extension to any B-lymphomas

8/11/2019 150914_CLS-Corp

43/53

!"#$"%&"' )*+, 43

Phase I early results providing solid rationale for GO/ NO GO decision" Tumor burden lysis at day 8-15" Safety profile (cytokine release syndrome)

Low capital investment versus protein manufacturing" cGMP manufacturing for Cellectis products in 200-300sqm facility

sufficient for initial clinical phases

Short manufacturing cycle < 20 days (w/o release testing)

Cost effective" Contained manufacturing COGs (

8/11/2019 150914_CLS-Corp

44/53

Roll out in liquid and solid tumor indications

8/11/2019 150914_CLS-Corp

45/53

8/11/2019 150914_CLS-Corp

46/53

!"#$"%&"' )*+,

Broad CAR T cell pipeline(1)

46

(*) Subject to an exclusive worldwide option agreement with Servier (S2-S6, targets undisclosed)(**) Target under Pfizer-Cellectis joint research effort

UCART19 (*)

UCART123

UCARTCS1

UCART38 (**)

S-2 (*)S-3 (*)

S-4 (*)

S-6 (*)

S-5 (*)

Q3 2015

Q3 2014

Q2 2015

Q1 2015

Q1 2015

Q2 2015

Q3 2015

Q3 2015

! CD19+ B cell malignancies

!Acute myeloid leukemia (AML)

! Multiple myeloma (MM)

! Multiple myeloma (MM)

Discovery Preclinical Phase I

(1) Not including 15 targets in Pfizer alliance

Q2 2015

8/11/2019 150914_CLS-Corp

47/53

!"#$"%&"' )*+,

On March the 7th

, Cellectis has entered into an alliance with Servier

" Scope: development of UCART19 in B-cell malignancies 5 other candidates in solid tumors

" Responsibilities: Cellectis will be responsible for the R&D of certain candidates through the end of clinical

phase I. Servier may exercise an exclusive worldwide option for each candidate developed under

the agreement. Upon exercising each option, Servier will be responsible for taking over clinical

development, registration and commercialization of each product.

" Financials:

Upfront payment of $10 million Up to $140 million for each of the six candidates potentially developed, spread over

various milestones in the development and commercialization phases. In addition, Cellectis will receive royalties on the sales of commercialized products.

Alliance with Servier

47

8/11/2019 150914_CLS-Corp

48/53

!"#$"%&"' )*+,

On June the 18th, Cellectis has entered into an alliance with Pfizer

" Scope: development of CAR-T cell therapies in oncology

15 Pfizer targets 12 Cellectis targets

" Exclusivity: For 4 years, Cellectis will not enter into another preclinical CAR-T alliance in oncology

No exclusivity on each Cellectis product once IND filed

" Responsibilities: Both companies work together on preclinical research for 15 Pfizer targets and 4 Cellectis targets (the

other 8 Cellectis targets are developed outside the alliance). Each company is responsible and has all worldwide rights for clinical development and commercialization

of any product directed at its own targets. Pfizer has right of first refusal on the products directed at the 4 Cellectis targets developed in the alliance.

" Financials: Upfront payment of $80 million Up to $185 million for each product targeting a Pfizer target potentially developed, spread over

various milestones in the development and commercialization phases.

In addition, Cellectis will receive royalties on the sales of commercialized products.

" Equity: Pfizer purchased about 10% of Cellectis capital through newly issued shares at a price of !9.25 per

share.

Alliance with Pfizer

48

8/11/2019 150914_CLS-Corp

49/53

Financials & Conclusion

8/11/2019 150914_CLS-Corp

50/53

!"#$"%&"' )*+,

Ad hoc world class scientific & medical Advisory Board of key opinion leaders in oncology

and cell therapy: Professor Ton Schumacher

Professor Alain Fischer

Professor Vronique Leblond

Professor David Linch

Professor Herv Dombret

Consultants:

Christopher A. Bravery, PhD (for Pharm. Assesor MHRA)

Paul Chamberlain, PhD (former Reg. Specialist Amgen, former Director Drug Dev.Prog. MDS)

Mickael Kamarck (former President Merck Biologicals and vaccines)

Dr. Bruce Burlington, M.D. (former president Wyeth regulatory affairs)

Best-in-class expertise for development

50

8/11/2019 150914_CLS-Corp

51/53

!"#$"%&"' )*+, 51

Shareholding structure built to foster growth

Breakdown of capital as of August 29, 2014(27,9 million shares*)

# !319 M market capitalization (August 29, 2014)

# Significant increase in liquidity

! 220,000 shares traded / day in 2014 YTD

! 105,000 shares traded / day in 2013! 20,000 shares traded / day in 2012! 16,000 shares traded / day in 2011 Founders: 7,2%

International float: 42,3%

BPI: 11,3%

Family offices: 15,1%

*32.5 million on a fully diluted basis

Pfizer: 10,0%

# Shareholding structure in line with the growthstrategy

# Float of ~ 56 %

French float: 14.1%

8/11/2019 150914_CLS-Corp

52/53

!"#$"%&"' )*+, 52

Management team & board of directors

MANAGEMENT

# Andr Choulika, Chairman and CEO

# David Sourdive, Executive Vice PresidentCorporate Development

# Mathieu Simon, Executive Vice President

#

Thierry Moulin, Chief Financial Officer

# Philippe Duchateau, Chief Scientific Officer

# Philippe Valachs, Company Secretary

BOARD OF DIRECTORS

#Andr Choulika Ph.D.

# David Sourdive Ph.D.

# Mathieu Simon M.D.

# Laurent Arthaud

#Annick Schwebig M.D.

# Pierre Bastid

#Alain Godard

# Roger J. Hajjar M.D.

8/11/2019 150914_CLS-Corp

53/53

?LEMN O3F Cellectis8 rue de la Croix Jarry75013 ParisFrance

www.cellectis.com

Tel. : +33 (0) 1 81 69 16 00